The OS was 9.53 and 15.64 months, and the ORR was 5.0 and 18.3% in patients with and without BRAF-mutated melanoma, respectively (Supplementary Tables S1 and S3), although the difference was not statistically significant. This evidence concerns the gene BRAF and melanoma.